

## Review Article

**Plant-derived Health-Effects of Turmeric and Curcumenoids**

Stig Bengmark

Lund University, Lund, Sweden

London University, Departments of Hepatology and Surgery, Institute of Hepatology, University College, London Medical School, United Kingdom

Kuwait Medical Journal 2006, 38 (4): 267-275

**ABSTRACT**

The world suffers an epidemic of both critical (CI) and chronic illnesses (ChDs), and both increase from year to year, and have done so for several decades. It is strongly associated to modern, so called Western, life style: stress, lack of exercise, abuse of tobacco and alcohol, and to the transition from natural unprocessed foods to processed, calorie-condensed and heat-treated foods. There is a strong association between ChDs and reduced intake of plant fibres, plant antioxidants and increased consumption of industrially produced and processed products especially dairy, refined sugar and starch products. Heating up foods such as milk (pasteurization), and production of and storage of milk powder, produces

large amounts of advanced glycation products (AGEs) and advanced lipoxidation products (ALEs), known as potent inducers of inflammation. Numerous plant-derived, but also microbe-derived, substances, often referred to as chemopreventive agents, have documented anti-inflammatory effects and are believed to reduce speed of aging, prevent degenerative malfunctions of organs and development of acute and chronic diseases. Among them are various curcumenoids found in turmeric curry foods and, thousands more of hitherto less or unexplored substances. This review focuses on documented experimental and clinical effects of supplementation of turmeric, various curcumenoids and pure curcumin.

**AN EPIDEMIC OF CHRONIC DISEASES AND CRITICAL ILLNESS**

Modern medicine has to a large extent failed in its ambition to control both acute and chronic diseases. In acute diseases; those defined as medical and surgical emergencies such as myocardial infarction, stroke and severe pancreatitis, and those related to advanced medical and surgical treatments, such as stem cell transplantation or advanced surgical operations, there is an unacceptably high morbidity and co-morbidity. Furthermore, the world suffers an epidemic of chronic diseases of a dimension never seen before, and these diseases are now like a prairie fire also spreading to so-called developing countries. Chronic diseases - including diseases such as cardiovascular and neurodegenerative conditions, diabetes, stroke, cancers and respiratory diseases - constitute 46% of the global disease burden and 59% of the global deaths today; each year on earth, approximately (app) 35 million individuals will die in conditions related to chronic diseases, and the numbers are increasing and have done so for several years<sup>[1]</sup>. Similarly, the morbidity related to advanced medical and surgical treatments and emergencies, especially infectious complications, is also fast increasing. Sepsis is the most common medical and surgical complication, estimated only

in the US to annually affect as many as 751,000<sup>[2,3]</sup>, and cause the death of app 215, 000 patients (29%)<sup>[3]</sup>. This makes sepsis the tenth most common cause of death in the country. It is especially alarming that both morbidity and mortality in critical illness (CI), especially when septic, is fast increasing and has done so for several decades. With a documented 1.5% rate of increase per year it might double within the coming 50 to 60 years.

**LIFE-STYLE ASSOCIATED DISEASES**

Accumulating evidence supports the association of ChDs to modern life style, stress, lack of exercise, abuse of tobacco and alcohol, and to the transition from natural unprocessed foods to processed, calorie-condensed and heat-treated foods. There is a strong association between ChD and reduced intake of plant fibres, plant antioxidants and increased consumption of industrially produced and processed dairy products, refined sugars and starch products. The per capita consumption of refined sugar has increased from about 0.5 kg per person per year in 1850 to almost 50 kg/person/year in the year 2000 and the per cow milk production from 2 to 50 liters/day. Dairy products, especially milk (mostly from pregnant cows) are rich in pro-inflammatory molecules: hormones such as

Address correspondence to:

Stig Bengmark, MD, PhD, FRACS (hon), FRCPS (hon), 185 Barrier Point Road, Royal Docks, London, E16 2SE, United Kingdom. Tel & Fax: +44 20 7511 6842. E-mail: s.bengmark@ucl.ac.uk

estrogens and growth factors such as IGF-1. Consumption of bovine milk has also been shown to release inflammatory mediators, increase intestinal permeability and induce leakage of larger molecules such as albumin and hyaluronan into the body. Heating up milk (pasteurization), and especially production of and storage of milk powder, produces large amounts of advanced glycation products (AGEs) and advanced lipoxidation products (ALEs)<sup>[4]</sup>, known as potent inducers of inflammation. This information is especially important as many foods such as icecream, enteral nutrition solutions and baby formulas are based on milk powder. Bread, especially from gluten-containing grains, is also rich in molecules with documented pro-inflammatory effects, and bread crust is often used experimentally to induce inflammation (See further Bengmark)<sup>[5-7]</sup>.

### PLANT-DERIVED PROTECTION

Common to those suffering from ChD as well as CI is that they suffer an increased degree of inflammation, most likely due to their Western lifestyle. We are increasingly aware that plant-derived substances, often referred to as chemo-preventive agents, have an important role to play in the control of inflammation. These substances are not only inexpensive, they are also easy available, and have no or limited toxicity. Among these numerous chemo-preventive agents are a whole series of phenolic and other compounds believed to reduce speed of aging and prevent degenerative malfunctions of organs, among them various curcumenoids found in turmeric curry foods and, thousands more of hitherto less or unexplored substances. However, this review will mainly focus on curcumin and its effects.

Polyphenols have in the recent few years received increasing attention for their strong chemo-preventive ability. Curcumin and many other plant-derived substances are increasingly regarded as shields against disease. Curcumin is the most explored of the so called curcumenoids, a family of chemo-preventive substances present in the spice turmeric. Although the substance has been known for some time, it is in the most recent years that the interest has exploded, much in parallel with increasing concern for severe side-effects of synthetic COX-2 inhibitors, marketed by pharmaceutical industry. Most of the reported curcumin studies in the literature are experimental and few clinical studies are thus far presented.

### CURCUMIN - AN ANTIOXIDANT AND INHIBITOR OF NF- $\kappa$ B, COX-2, LOX AND INOS

NF- $\kappa$ B plays a critical role in several signal

transduction pathways involved in chronic inflammatory diseases<sup>[8]</sup> such as asthma and arthritis and various cancers<sup>[9]</sup>. Activation of NF- $\kappa$ B is linked with apoptotic cell death; either promoting or inhibiting apoptosis, depending on cell type and condition. The expression of several genes such as cyclo-oxygenase-2 (COX-2), matrix metalloproteinase-9 (MMP-9), inducible nitric oxide synthase (iNOS), tumor necrosis factor (TNF), interleukin-8 (IL-8), eotaxin, cell surface adhesion molecules and anti-apoptotic proteins are regulated by NF- $\kappa$ B<sup>[10]</sup>. COX-2 is inducible and barely detectable under normal physiological conditions, but is rapidly, but transiently, induced as an early response to pro-inflammatory mediators and mitogenic stimuli including cytokines, endotoxins, growth factors, oncogenes and phorbol esters. COX-2 synthesizes series-2 prostaglandins (PGE<sub>2</sub>, PGF<sub>2</sub>-), which contribute to inflammation, swelling and pain. PGE<sub>2</sub> promotes production of IL-10, a potent immuno-suppressive cytokine produced especially by lymphocytes and macrophages, and suppression of IL-12<sup>[11]</sup>. Inducible nitric oxide synthase (iNOS), activated by NF- $\kappa$ B is another enzyme that plays a pivotal role in mediating inflammation, especially as it acts in synergy with COX-2.

### TURMERIC - APPROVED AS FOOD ADDITIVE

Curcumin, (1,7-bis (4-hydroxy-3-methoxyphenol)-1,6 heptadiene-3,5-dione), a polyphenol rich in the dietary spice turmeric, is received from dried rhizomes of the perennial herb *Curcuma longa* Linn, a member of the ginger family. Turmeric is mainly known for its excellent ability to preserve food and is approved as food additive in most Western countries. It is produced in several Asian and South-American countries. In India alone about 500,000 metric tons are produced each year, of which about half is exported. It has, in addition to extensive use as food additive, for generations also been used in traditional medicine for treatment of various external or internal inflammatory conditions such as arthritis, colitis and hepatitis.

The molecule of curcumin resembles ubiquinol and other phenols known to possess strong antioxidant activities. Its bioavailability on oral supplementation is low, but can be improved by dissolution in ambivalent solvents (glycerol, ethanol, DMSO)<sup>[12]</sup>. It is also reported to be dramatically elevated by co-ingestion of piperine (a component of pepper), demonstrated both in experimental animals and humans<sup>[13]</sup>. Several studies have demonstrated that curcumin is atoxic, also in very high doses<sup>[14,15]</sup>. Treatment of humans for three months with 8000 mg curcumin per day showed no side effects<sup>[15]</sup>. It is estimated that adult

Indians consume 80-200 mg curcumin per day<sup>[16]</sup>. A common therapeutic dose is 400-600 mg curcumin three times daily corresponding to up to 60 g fresh turmeric root or about 15 g turmeric powder. The content of curcumin in turmeric is usually 4-5 %.

### CURCUMIN- EFFECTIVE AGAINST STRESS-INDUCED OVERINFLAMMATION

Curcumin is not only an inexpensive atoxic and potent COX-2 and iNOS inhibitor<sup>[17]</sup>, it is also a potent inducer of heat shock proteins (HSPs) and potential cytoprotector<sup>[18,19]</sup>. Curcumin does not only inhibit COX-2, it also inhibits lipoxygenases (LOX) and leukotrienes such as LBT4 and 5HETE<sup>[20]</sup>, especially when bound to phosphatidylcholine micelles<sup>[21]</sup>. It is also reported to inhibit cytochrome P450 isoenzymes and thereby activation of carcinogens<sup>[22]</sup>. Curcumin has the ability to intercept and neutralize potent pro-oxidants and carcinogens, both ROS (superoxide, peroxy, hydroxyl radicals) and NOS (nitric oxide, peroxynitrite)<sup>[23]</sup>. It is also a potent inhibitor of TGF- and fibrogenesis<sup>[24]</sup> which is one of the reasons, why it can be expected to have positive effects in diseases such as kidney fibrosis, lung fibrosis, liver cirrhosis and Crohn's Disease and in prevention of formation of tissue adhesions<sup>[25]</sup>. Curcumin is suggested to be especially effective in Th1-mediated immune diseases as it effectively inhibits Th1 cytokine profile in CD4<sup>+</sup> T cells by interleukin-12 production<sup>[26]</sup>.

Many medicinal herbs and pharmaceutical drugs are therapeutic at one dose and toxic at another, and interactions between herbs and drugs, even if structurally un-related, may increase or decrease the pharmacological and toxicological effects of either component<sup>[27,28]</sup>. It is suggested that curcumin may increase the bioavailability of vitamins such as vitamin E and also decrease cholesterol, as curcumin in experimental studies significantly raises the concentration of -tocopherol in lung tissues and decreases plasma cholesterol<sup>[29]</sup>. Polyphenols, isothiocyanates such as curcumin and flavonoids such as resveratrol, are all made accessible for absorption into the intestinal epithelial cells and the rest of the body by digestion/fermentation in the intestine by microbial flora<sup>[30]</sup>.

### CURCUMIN IN ACUTE AND CHRONIC DISEASES

**Atherosclerosis:** Oxidation of low density lipoproteins (LDL) is suggested to play a pivotal role in the development of arteriosclerosis, and LDL oxidation products are toxic to various types of cells including endothelial cells. Curcumin has a strong capacity to prevent lipid peroxidation, stabilize cellular membranes, inhibit proliferation

of vascular smooth muscle cells, and inhibit platelet aggregation; all important ingredients in the pathogenesis of arteriosclerosis. Curcumin was found to be the most effective and quercetin the least, when curcumin, quercetin and capsaicin were compared for their ability to inhibit the initiation and propagation phases of LDL oxidation of a defined antioxidant butylated hydroxy anisole (BHA)<sup>[31]</sup>. Supply of curcumin, but also capsaicin and garlic (allicin) to rats fed a cholesterol-enriched diet prevented both increase in membrane cholesterol and increased fragility of the erythrocytes<sup>[32]</sup>. Significant prevention of early atherosclerotic lesions in thoracic and abdominal aorta are observed in rabbits fed an atherogenic diet for thirty days, accompanied by significant increases in plasma concentrations of coenzyme Q, retinol and -tocopherol and reductions in LDL conjugated dienes and in TBARS (thiobarbituric acid-reactive substances, an expression of ongoing oxidation)<sup>[33]</sup>.

**Cancer:** Cancer is a group of more than 100 different diseases, which manifest itself in uncontrolled cellular reproduction, tissue invasion and distant metastases<sup>[34]</sup>. Behind the development of these diseases are, most often, exposure to carcinogens, which produce genetic damage and irreversible mutations, if not repaired. During the last fifty years attempts have been made to find or produce substances that could prevent these processes, so called chemopreventive agents. Cancers are generally less frequent in the developing world, which has been associated both with less exposure to environmental carcinogens and to a richer supply of natural chemopreventive agents. The incidence per 100, 000 population is in the USA considerably higher for the following diseases compared to India: prostatic cancer (23 X), melanoma skin cancer (male 14 X, female 9 X), colorectal cancer (male,11 X, female 10 X), endometrial, cancer (9 X), lung cancer (male 7 X, female 17 X), bladder cancer (male 7 X, female 8 X) breast cancer (5 X), renal cancer (male 9 X, female 12 X)<sup>[35]</sup>. These differences are even greater for some diseases such as breast cancer and prostatic cancer when compared to China. The consumption of saturated fat and sugary foods is much less in the Asian countries, but equally important, the consumption of plants with high content of chemopreventive substances is significantly higher in these countries. As an example, the consumption of curcumin has for centuries been about 100 mg/day in these Asian countries<sup>[36]</sup>. Curcumin induces *in vitro* apoptosis of various tumour cell lines: breast cancer cells<sup>[36,37]</sup>, lung cancer cells<sup>[38]</sup>,

human melanoma cells<sup>[39]</sup>, human myeloma cells<sup>[40]</sup>, human leukemia cell lines<sup>[41]</sup>, human neuroblastoma cells<sup>[42]</sup>, oral cancer cells<sup>[43]</sup>, prostatic cancer cells<sup>[44-47]</sup>. Curcumin has in experimental models also demonstrated ability to inhibit intrahepatic metastases<sup>[48]</sup>. Few *in vivo* experimental studies and no clinical controlled trials are this far concluded. However, a recent phase I study reported histologic improvement of precancerous lesions in one out of two patients with recently resected bladder cancer, two out of seven patients of oral leucoplakia, one out of six patients of intestinal metaplasia of the stomach, and two out of six patients with Bowen's disease<sup>[49]</sup>. However, the main purpose of the study was to document that curcumin is not toxic to humans when taken by mouth for three months in a dose of up to 8,000 mg/day.

**Diabetes:** Turmeric (TU, 1 g/kg body weight) or curcumin (CU, 0.08 g/kg body weight) were in a recent study supplied daily for three weeks to rats with alloxan-induced diabetes (AID) and compared to controls (CO)<sup>[50]</sup>. Significant improvements were observed in blood glucose (mg/dl CO 88.3, AID 204.4, TU 142.7, CU 140.1), hemoglobin (gm/dl CO 14.7, AID 10.8, TU 13.6, CU 13.1) and glycosylated hemoglobin (gm/dl CO 2.8, AID 11.2, TU 9.0, CU 7.8). Significant differences were also observed in TBARS in liver tissue (nmoles/g tissue CO 43.0, AID 54.0, TU 34.0, CU 29.0), TBARS in plasma (nmoles/ml CO 3.8, AID 7.3, TU 5.3, CU 4.6), in glutathione in liver ( $\mu$ gm/mg CO 23.4, AID 11.2, TU 16.6, CU 20.9) and glutathione in plasma (mg/dl CO 22.4, AID 14.2, TU 18.4, CU 20.1). It was also observed that the activity of sorbitol dehydrogenase (SDH), which catalyzes the conversion of sorbitol to fructose, was significantly lowered by treatment both with turmeric and curcumin.

**Gastric diseases:** When the *in vitro* effects against 19 different *Helicobacter pylori* strains, including five cag A+ strains (cag A is the strain-specific *H pylori* gene linked to premalignant and malignant lesions) were studied, both treatments were found to be equally effective as both treatments did significantly reduce growth of all the strains studied<sup>[51]</sup>. Subsequent studies did also demonstrate that curcumin inhibits infection and inflammation of gastric mucosal cells through the inhibition of activation of NF- $\kappa$ B, degradation of I $\kappa$ B, NF- $\kappa$ B DNA binding and the activity of I $\kappa$ B kinases and . No curcumin-induced effects were observed on mitogen-activated protein kinases (MAPK), extracellular signal regulating kinases  $1/2$  (ERK1/2) and p38. *H pylori*-induced mitogenic response was completely

blocked by curcumin<sup>[52]</sup>. Significant antifungal properties against various fungal, especially phytopathogenic, organisms by curcumin are also reported<sup>[53]</sup>.

**Hepatic diseases:** Dietary supply of curcuminoids is also reported to increase hepatic acyl-CoA and prevent high-fat diet-induced accumulation in the liver and adipose tissues in rats<sup>[54]</sup>. Ethanol-induced steatosis is known to be further aggravated by supply of PUFA-rich vegetable oils, which has been thermally oxidized. Rats fed for 45 days with a diet containing 20 % ethanol and 15 % sunflower oil, heated to 180° C for 30 min (AO), showed extensive histopathological changes with focal and feathery degeneration, micronecroses and extensive steatosis in the liver and extensive inflammation, vessel congestion and fatty infiltration in the kidneys, changes, which could largely be prevented by simultaneous supply of curcumin (CU) or particularly photo-irradiated curcumin (PCU) e.g. curcumin kept in bright sunshine for five hours<sup>[55]</sup>. Both products were supplied in a dose of 80 mg/kg body weight. Both products did significantly inhibit elevations in alkaline phosphatases (ALP): controls (CO) 85.88, PCU 239.56, CU 177.41 and PCU 149.15 and  $\gamma$ -glutamyl transferase (GGT): CO 0.60, PCU 2.51, CU 1.43, PCU 1.15. Similar beneficial effects were observed on histology in various tissues and in hepatic content of cholesterol, triglycerides free fatty acids and phospholipids. In another study, rats were fed with fishoil and ethanol (FE) for four weeks which resulted in hepatic lesions consisting of a fatty liver, necrosis and inflammation. Supply of curcumin in a daily dose of 75 mg/kg body weight to these rats prevented the histological lesions<sup>[56]</sup>. Curcumin was observed in part to suppress NF- $\kappa$ B-dependent genes, to block endotoxin-mediated activation of NF- $\kappa$ B and to suppress the expression of cytokines, chemokines, COX-2 and iNOS in Kupffer cells. Similar effects were also observed in carbon tetrachloride-induced injuries. Pretreatment for four days with curcumin (100 mg/kg body weight) before intraperitoneal injection of CCl<sub>4</sub> prevented subsequent increases in TBARS significantly: CO 274, CCl<sub>4</sub> 556, CU 374, alanine aminotransferase (ALT): CO 46, CCl<sub>4</sub> 182, CU 97 and aspartate aminotransferase (AST): CO 97, CCl<sub>4</sub> 330, CU 211 and in hydroxyproline ( $\mu$ g/g liver tissue): CO 281, CCl<sub>4</sub> 777, CU 373<sup>[57]</sup>.

**Intestinal diseases:** Pretreatment for ten days with curcumin in a daily dose of 50 mg/kg body weight before induction of trinitrobenzene sulphonic acid (TNBS) colitis resulted in a significant reduction in

degree of histological tissue injury, neutrophil infiltration (measured as decrease in myeloperoxidase activity) and lipid peroxidation (measured as decrease in malondialdehyde activity) in the inflamed colon and in a decreased serine protease activity<sup>[58]</sup>. A significant reduction in NF- $\kappa$ B activation and reduced levels of NO and a marked suppression of Th1 functions: IFN and IL-12p40 mRNA, was also observed. Curcumin was in another similarly designed study added to the diet for five days before induction of TNBS colitis, which resulted in a significant reduction in myeloperoxidase, and attenuation of the TNBS-induced message for IL-1 on semiquantitative RT-PCR<sup>[59]</sup>. Western blotting revealed a significant attenuation of the activation of p38 MAPK. Curcumin was also supplied in combination with caffeic acid phenethyl ester (CAPE) to animals treated with cytostatic drugs (arabinose cytosine, Ara-C, and methotrexate, MTX)<sup>[59]</sup>. The treatment did not only inhibit the NF- $\kappa$ B induced mucosal barrier injury but was also shown to increase the *in vitro* susceptibility of the non-transformed small intestinal rat epithelial cell, IEC-6, to the cytostatic agents.

**Neurodegenerative diseases:** A growing body of evidence implicates free radical toxicity, radical induced mutations and oxidative enzyme impairment and mitochondrial dysfunction in neurodegenerative diseases (NDD). Significant oxidative damage is observed in all NDDs, which in the case of Alzheimer disease (AD) leads to extracellular deposition of  $\beta$ -amyloid (A $\beta$ ) as senile plaques. Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen have proved effective in preventing progress of AD in animal models<sup>[60]</sup> but gastrointestinal and occasional liver and kidney toxicity induced by inhibition of COX-1 precludes widespread chronic use of the drug<sup>[61]</sup>. Use of antioxidants such as vitamin E ( $\alpha$ -tocopherol) has proven rather unsuccessful even when high doses were used<sup>[62]</sup>. Vitamin E,  $\alpha$ -tocopherol, is in contrast to  $\alpha$ -tocopherol a poor scavenger of nitric oxide-(NO) based free radicals. Curcumin is several times more potent a scavenger than vitamin E<sup>[63]</sup> and in addition also a specific scavenger of NO-based radicals<sup>[64]</sup>. When tried in a transgenic mouse model of AD, a modest dose (24 mg/kg body weight), but not a > 30 times higher dose (750 mg/kg body weight) of curcumin significantly reduce oxidative damage and amyloid pathology<sup>[65]</sup>. Similar observations, reductions in both A $\beta$  deposits and in memory deficits are also made in Sprague Dawley rats<sup>[66]</sup>. The age-adjusted prevalence of both AD<sup>[67]</sup> and Parkinson's disease (PD) is in India<sup>[68]</sup> with its

significantly higher intake of turmeric, much lower than in Western countries, especially the USA. However, the preventive effects of consumption of turmeric can also be achieved with other polyphenol-rich fruits and vegetables if consumed in enough quantities. Blueberries, strawberries and spinach in doses of 18.6, 14.8 and 9.1 gm of dried extract/kg body weight were demonstrated to be effective in reversing age-related deficits in both neuronal and behavioural parameters<sup>[69]</sup>. A study from 1999 is of special interest: Rats on chronic ethanol supply were randomized to 80 mg/kg body weight of curcumin (CU) or control (CO) and compared to non-intoxicated normal rats (NI)<sup>[70]</sup>. The degree of histopathological changes, the levels of TBARS (NI 1.29, CU 2.41, CO 2.98), cholesterol (NI 1531.9, CU 1658.2, CO 2031.1), phospholipids (NI 1845.5, CU 2011.5, CO 2795.1), and free fatty acids (NI 26.7, CU 39.9, CO 53.1) in brain tissue were significantly improved after curcumin treatment.

**Ocular diseases:** Cataract, an opacity of the eye lens, is the leading cause of blindness worldwide, responsible for the blindness of almost 20 million people in the world<sup>[71]</sup>. Nutritional deficiencies, especially lack of consumption of enough antioxidants, diabetes, excessive sunlight, smoking and other environmental factors are known to increase the risk of cataracts<sup>[72]</sup>. The age-adjusted prevalence of cataract in India is, however, three times that of the United States<sup>[73]</sup>. Despite this, three different experimental studies have reported significant preventive effects of curcumin against cataracts induced by naphthalene<sup>[74]</sup>, galactose<sup>[75]</sup> and selenium<sup>[76]</sup>.

**Pancreatic diseases:** The effect of curcumin to reduce the damage to pancreas was studied in two different models; cerulein-induced and ethanol and CCK-induced pancreatitis<sup>[77]</sup>. Curcumin was administered intravenously in parallel with induction of pancreatitis. A total of 200 mg/kg body weight was administered during the treatment period of six hours. Curcumin treatment significantly reduced histological injuries, the acinar cell vacuolization and neutrophil infiltration of the pancreatic tissue, the intrapancreatic activation of trypsin, the hyperamylasemia and hyperlipasemia, and the pancreatic activation of NF- $\kappa$ B, I $\kappa$ B degradation, activation of activator protein (AP)-1 and various inflammatory molecules such as IL-6, TNF- $\alpha$ , chemokine KC, iNOS and acidic ribosomal phosphoprotein (ARP). Curcumin did also significantly stimulate pancreatic activation of caspase-3 in both models.

**Respiratory diseases:** As mentioned above, curcumin is a potent inhibitor of TGF- and fibrogenesis<sup>[25]</sup> and is thought to have positive effects in fibrotic diseases in kidneys, liver, intestine (Crohn's Disease), body cavities (prevention of fibrous adhesions)<sup>[19]</sup> and on conditions with lung fibrosis, including cystic fibrosis. The latter is of special interest as it has been especially linked to glutathione deficiency. The effect of curcumin against amiodarone-induced lung fibrosis was recently studied in rats<sup>[78]</sup>. Significant inhibition of LDH activity, infiltration of neutrophils, eosinophils and macrophages in lung tissue, LPS-stimulated TNF- release, phorbol myristate acetate (PMA)-stimulated superoxide generation, myeloperoxidase (MPO) activity, TGF- 1 activity, lung hydroxyproline content and expression of type I collagen and c-Jun protein were observed when curcumin was supplemented in doses of 200 mg/kg body weight in parallel with intratracheal instillation of 6.25 mg/kg body weight of amiodarone. Curcumin exhibits structural similarities to isoflavonoid compounds that seem to bind directly to the CFTR protein and alter its channel properties<sup>[79]</sup>. Egan *et al*<sup>[80]</sup>, who had previously observed that curcumin inhibits a calcium pump in endoplasmic reticulum, thought that reducing the calcium levels might liberate the mutant CFTR and increase its odds of reaching the cell surface (see also)<sup>[81]</sup>. The F508 mutation, the most common cause of cystic fibrosis, will induce a misprocess in the endoplasmic reticulum of a mutant cystic fibrosis transmembrane conductance regulator (CFTR) gene. A dramatic increase in survival rate and in normal cAMP-mediated chloride transport across nasal and gastrointestinal epithelia was observed in gene-targeted mice homozygous for the F508 when supplemented curcumin<sup>[79]</sup>. No human studies are yet reported and it is too early to know if this treatment will be able to halt or reverse the decline in lung function also in patients with cystic fibrosis. An eventual anti-asthmatic effect of curcumin was recently tested in guinea-pigs sensitized with ovalbumin and significant reductions observed both in airway constriction and in airway hyperreactivity to histamine<sup>[82]</sup>.

**Tobacco/cigarette smoke (CS)-induced injuries:** CS is suggested to cause 20% of all deaths and ~30% of all deaths from cancer. CS contains thousands of compounds of which about hundred are known carcinogens, co-carcinogens, mutagens and/or tumor promoters. Each puff of smoke contains over 10 trillion free radicals. Antioxidant levels in blood are also significantly reduced in smokers. Activation of NF- $\kappa$ B has been implicated in chemical carcinogenesis and tumorigenesis

through activation of several genes such as COX-2, iNOS, matrix metalloproteinase ((MMP)-9, IL-8, cell surface adhesion molecules anti-apoptotic protein and others. A recent study reports that curcumin abrogates the activation of NF- $\kappa$ B, which correlates with down-regulation of COX-2, MMP-9 and cyclin D1 in human lung epithelial cells<sup>[83]</sup>.

#### PLANT ANTIOXIDANTS - RELEASED BY GI MICROBES (Flora)

All chronic diseases are in a way related. They all develop as a result of a prolonged and exaggerated inflammation<sup>[84]</sup>. Their development can most likely be prevented or at least delayed by extensive consumption of antioxidants such as curcumin. It is important to remember, that it is almost exclusively through microbial fermentation of the different plants that bioactive antioxidants are released and absorbed. Clearly flora and supplied lactic acid bacteria/probiotics play an important role. It is therefore unfortunate that both size and diversity of flora is impaired and intake of probiotic bacteria significantly reduced among Westerners. For example, reduction in total numbers and diversity of flora is also associated with certain chronic diseases such as IBD<sup>[85]</sup>. A study from 1983 demonstrated that *Lb plantarum*, a strong fibre fermentor, is found in only 25% of omnivorous Americans and in about 2/3 of vegetarian Americans<sup>[86]</sup>. Great differences in volume and diversity of flora have also been observed between different human cultures. It is reported that Scandinavian children as compared to Pakistani children have a much reduced flora<sup>[87]</sup>. Astronauts, who return from space flights have during the flight lost most of their commensal flora including lactobacillus species such as *Lb plantarum* (lost to almost 100%), *Lb casei* (lost to almost 100%), *Lb fermentum* (reduced by 43%), *Lb acidophilus* (reduced by 27%), *Lb salivarius* (reduced by 22%) and *Lb brevis* (reduced by 12%)<sup>[88]</sup>, changes most likely attributed to poor eating (dried food, no fresh fruits and vegetables) and a much reduced intake of plant fibers and natural antioxidants, to the mental and physical stress and eventually also to the lack of physical exercise. Many individuals in Western Societies exhibit a type of "astronaut-like lifestyle" with unsatisfactory consumption of fresh fruits, vegetables, too much stress and no or little outdoor/sport activities. Furthermore, flora seems not to tolerate exposure to chemicals including pharmaceuticals. This is also demonstrated in critically ill, who most often have lost their entire *lactobacillus* flora<sup>[89]</sup>. A recent Scandinavian study suggest that fiber-fermenting LAB such as *Lb plantarum*, *Lb rhamnosus* and *Lb paracasei* ssp *paracasei*, present in all humans with a rural

lifestyle, are only found 52%, 26% and 17% respectively of persons with a more urban Western type lifestyle<sup>[90]</sup>. These LAB are present in all with more rural lifestyle. The lack of these LAB is probably negative as these LAB are unique in their ability to ferment important fibers such as inulin and phlein, otherwise resistant to fermentation by most *Lactobacillus* species<sup>[91]</sup>, and superior to other *Lactobacillus* in their ability to eliminate pathogenic microorganisms such as *Clostridium difficile*<sup>[92]</sup>.

### CONCLUSIVE REMARKS

To use medicinal plants and their active components is becoming an increasingly attractive approach for the treatment of various inflammatory disorders among patients unresponsive or unwilling to take standard medicines. Food derivatives have the advantage of being relatively nontoxic. This is certainly so for turmeric and curcumin. If one chooses to supply it with the fiber, e.g., as turmeric, additional supplementation with probiotic bacteria will most likely enhance the efficacy of treatment.

Increasing evidence suggests that as saturated fat in the diet increases and plant fibre intake reduces the inflammatory reaction in the body increases<sup>[93]</sup>. A high fat/low fibre diet is clearly associated with chronic diseases<sup>[94]</sup> and fruit and vegetable intake with reduction in incidence of chronic diseases<sup>[95]</sup>. Focus is increasingly turning from fibre *per se* to active ingredients in the plant fibres, antioxidants and anti-inflammatory agents such as curcuminoids in turmeric.

Not only turmeric and curcumin, but also numerous other plants contain compounds which reduce inflammation and protect against disease. Among them are several thousands of plant-derived chemo-preventive agents, polyphenols and many other, most often unexplored, substances, which seem to have potential to reduce inflammation, speed of aging, and prevent degenerative malfunctions of organs and development of chronic diseases. Among them isothiocyanates in cruciferous vegetables, anthocyanins and hydroxycinnamic acids in cherries, epigallocatechin-3-gallate (EGCG) in green tea, chlorogenic acid and caffeic acid in coffee beans and also in virgin tobacco leaves, capsaicin in hot chili peppers, chalcones in apples, eugenol in cloves, gallic acid in rhubarb, hisperitin in citrus fruits, naringenin in citrus fruits, kaempferol in white cabbage, myricetin in berries, rutin and quercetin in apples and onions, resveratrol and other procyanidin dimers in red wine and virgin peanuts, various curcumenoids, the main yellow pigments in turmeric curry foods, and daidzein and genistein from the soy bean. These compounds have all slightly different functions and seem to complement each other well.

### REFERENCES

1. World Health Organisation. Process for a global strategy on diet, physical activity and health. WHO Geneva February 2003.
2. Arias E, Smith BL. Deaths: preliminary data for 2001. Natl Vital Stat Rep 2003; 51:1-44.
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associated costs of care. Crit Care Med 2001; 29:1303-1310.
4. Baptista JAB, Carvalho RCB. Indirect determination of Amadori compounds in milk-based products by HPLC/ELSD/UV as an index of protein deterioration. Food Research International 2004; 37:739-747.
5. Bengmark S. Acute and "chronic" phase response - a mother of disease. Clin Nutr 2004; 23:1256-1266.
6. Bengmark S. Bio-ecological Control of the Gastrointestinal Tract: The Role of Flora and Supplemented Pro- and Synbiotics. Gastroenterol Clin North Am 2005; 34:413-436.
7. Bengmark S. Impact of nutrition on ageing and disease. Curr Opin Nutr Metab Care 2006; 9:2-7.
8. Bernes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336:1066-1071.
9. Amit S, Ben-Neriah Y. NF-kappaB activation in cancer: a challenge for ubiquitination- and proteasome-based therapeutic approach. Semin Cancer Biol 2003; 13:15-28.
10. Pahl HL. Activators and target genes of Rel/ NF-kB transcription factors. Oncogene 1999; 18:6853-6866.
11. Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase-2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000; 164:361-370.
12. Sharma RA, Ireson CR, Verschoyle RD, et al. Effects of dietary curcumin on glutathione S-transferase and malonaldehyde-DNA adducts in rat liver and colonic mucosa: relationship with drug levels. Clin Cancer Res. 2001; 7:1452-1458.
13. Shoba G, Joy D, Joseph T, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998; 64:1167-1172.
14. Bhavani Shankar TN, Shantha NV, Ramesh HP, et al. Toxicity studies on Turmeric (*Curcuma longa*): acute toxicity studies in rats, guinea pigs & monkeys. Indian J Exp Biol 1980; 18:73-75.
15. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of turmeric (*Curcuma Longa*). J Alternative and Complementary Medicine 2003; 9:161-168.
16. Grant KL, Schneider CD. Turmeric. Am J Health-Syst Pharm 2000; 57:1121-1122.
17. Surh Y-J, Chun K-S, Cha H-H, et al. Molecular mechanisms underlying chemo-preventive activities of anti-inflammatory phytochemicals: downregulation of COX-2 and iNOS through suppression of NF-kB activation. Mutation Research 2001; 480-481:243-268.
18. Dunsmore KE, Chen PG, Wong HR. Curcumin, a medicinal herbal compound capable of inducing the heat shock response. Crit Care Med 2001; 29:2199-2204.
19. Chang D-M. Curcumin: a heat shock response inducer and potential cytoprotector. Crit Care Med 2001; 29:2231-2232.
20. Wallace JM. Nutritional and botanical modulation of the inflammatory cascade - eicosanoids, cyclooxygenases and lipoxygenases - as an adjunct in cancer therapy. Integrative Cancer Therapies 2002; 1:7-37.
21. Began G, Sudharshan E, Udaya Sankar K, et al. Interaction of curcumin with phosphatidylcholine: a spectrofluorometric study. J Agric Food Chem 1999; 47:4992-4997.

22. Thapliyal R, Maru GB. Inhibition of cytochrome P450 isoenzymes by curcumins *in vitro* and *in vivo*. *Food and Chemical Toxicology* 2001; 39:541-547.
23. Jovanovic SV, Boone CW, Steenken S, *et al.* How curcumin preferentially works with water soluble antioxidants. *J Am Chem Soc* 2001; 23:3064-3068.
24. Gaedeke J, Noble NA, Border WA. Curcumin blocks multiple sites of the TGF- $\beta$  signaling cascade in renal cells. *Kidney International* 2004; 66:112-120.
25. Srinisan P, Libbus B. Mining MEDLINE for implicit links between dietary substances and diseases. *Bioinformatics* 2004; 20:1290-1296.
26. Kang BY, Song YJ, Kim KM, *et al.* Curcumin inhibits Th1 cytokine profile in CD4+ T cells by suppressing interleukin-12 production in macrophages. *Br J Pharmacol* 1999; 128:380-384.
27. Fugh-Berman A. Herb-drug interactions. *Lancet* 2000; 355:134-138.
28. Groten JP, Butler W, Feron VJ, *et al.* An analysis of the possibility for health implications of joint actions and interactions between food additives. *Reg. Toxicol Pharmacol* 2000; 31:77-91.
29. Kamal-Eldin A, Frank J, Razdan A, *et al.* Effects of dietary phenolic compounds on tocopherol, cholesterol and fatty acids in rats. *Lipids* 2000; 35:427-435.
30. Shapiro TA, Fahey JW, Wade KL, *et al.* Human metabolism and excretion of cancer chemoprotective glucosinolates and isothiocyanates of cruciferous vegetables. *Cancer Epidemiol Biomarkers Prev* 1998; 7:1091-1100.
31. Akhilender Naidu K, Thippeswamy NB. Inhibition of human low density lipoprotein oxidation by active principles from spices. *Mol Cell Biochem* 2002; 229:19-23.
32. Kempaiah RK, Srinivasan K. Integrity of erythrocytes of hypercholesterolemic rats during spices treatment. *Mol Cell Biochem* 2002; 236:155-161.
33. Quiles JL, Dolores Mesa M, César L, *et al.* Curcuma longa extract supplementation reduces oxidative stress and attenuates aortic fatty streak development in rabbits. *Arterioscler Throm Vasc Biol* 2002; 22:1225-1231.
34. Levi MS, Borne RF, Williamson JS. A review of cancer chemopreventive agents. *Current Medicinal Chemistry* 2001; 8:1349-1362.
35. Anderson SR, McDonald SS, Greenwald P. *J Postgrad Med* 2003; 49:222-228.
36. Choudhuri T, Pal S, Munna L, *et al.* Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. *FEBS Letters* 2002; 512:334-340.
37. Shao ZM, Shen ZZ, Liu CH, *et al.* Curcumin exerts multiple suppressive effects on human breast carcinoma cells. *Int J Cancer* 2002; 98:2002.
38. Pillai GR, Srivastava AS, Hassanein TI, *et al.* Induction of apoptosis in human lung cancer cells by curcumin. *Cancer Letters* 2004; 208:163-170.
39. Zheng M, Ekmekcioglu S, Walch ET, *et al.* Inhibition of nuclear factor- $\kappa$ B and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cells. *Melanoma Res* 2004; 14:165-171.
40. Han SS, Keum YS, Seo HJ, Surh YJ. Curcumin suppresses activation of NF- $\kappa$ B and AP-1 induced by phorbol ester in cultured human promyelocytic leukaemia cells. *J Biochem Molecul Biol* 2002; 35:337-242.
41. Bharti AC, Shishodia S, Reuben JM, *et al.* Nuclear factor- $\kappa$ B and STAT3 are constitutively active in CD138+ cells derived from myeloma patients and suppression of these transcription factors leads to apoptosis. *Blood* 2004; 103:3175-3184.
42. Lontas A, Yeger H. Curcumin and resveratrol induce apoptosis and nuclear translocation and activation of p53 in human neuroblastoma. *Anticancer Res* 2004; 24:987-998.
43. Elattar TMA, Virji AS. The inhibitory effect of curcumin. Genistein, quercetin and cisplatin on the growth of oral cancer cells *in vitro*. *Anticancer Res* 2000; 20:1733-1738.
44. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, *et al.* Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. *Oncogene* 2001; 20:7597-7609.
45. Nakamura K, Yasunaga Y, Segawa T, *et al.* Curcumin downregulates AR gene expression in prostate cancer cell lines. *Int J Oncol* 2002; 21:825-830.
46. Hour TC, Chen J, Huang CY, *et al.* Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21<sup>WAF1/CIP1</sup> and C/EBP expressions and suppressing NF- $\kappa$ B activation. *The Prostate* 2002; 51:211-218.
47. Deab D, Jiang H, Gao X, *et al.* Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor- $\kappa$ B through suppression of I $\kappa$ B phosphorylation. *Mol Cancer Ther* 2004; 3:803-812.
48. Ohadshi Y, Tsuchia Y, Koizumi K, *et al.* Prevention of intrahepatic metastasis by curcumin in an orthotopic implantation model. *Oncology* 2003; 65:250-258.
49. Cheng AL, Hsu CH, Lin JK, *et al.* Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. *Anticancer Res* 2001; 21:2895-2900.
50. Giltay EJ, Hoogeveen EK, Elbers JMH, *et al.* Insulin resistance is associated with elevated plasma total homocysteine levels in healthy, non-obese subjects. Letter to the Editor. *Atherosclerosis* 1998; 139:197-198.
51. Mahady GB, Pendland SL, Yun G, Lu ZZ. Turmeric (*Curcuma longa*) and curcumin inhibit the growth of *Helicobacter pylori*, a group 1 carcinogen. *Anticancer Research* 2002; 22:4179-4182.
52. Foryst-Ludwig A, Neumann M, Schneider-Brachert W, Naumann M. Curcumin blocks NF- $\kappa$ B and the mitogenic response in *Helicobacter pylori*-infected epithelial cells. *Biochem Biophys Res Com* 2004; 316:1065-1072.
53. Kim MK, Choi GJ, Lee HS. Fungal property of *Curcuma longa* rhizome-derived curcumin against phytopathogenic fungi in greenhouse. *J Agr Food Chem* 2003; 51:1578-1581.
54. Asai A, Miyazawa T. Dietary curcuminoids prevent high-fat diet-induced lipid accumulation in rat liver and epididymal adipose tissue. *J Nutr* 2001; 131:2932-2935.
55. Rukkumani R, Balasubashini S, Vishwanathan P, Menon VP. Comparative effects of curcumin and photo-irradiated curcumin on alcohol- and polyunsaturated fatty acid-induced hyperlipidemia. *Pharmacol Res* 2002; 46:257-264.
56. Nanji AA, Jokelainen K, Tipoe GL, *et al.* Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF- $\kappa$ B-dependent genes. *Am J Physiol Gastrointest Liver Physiol* 2003; 284:G321-G327.
57. Park EJ, Jeon CH, Ko G, *et al.* Protective effect of curcumin in rat liver injury induced by carbon tetrachloride. *J Pharm Pharmacol* 2000; 52:437-440.
58. Ukil A, Maity S, Karmakar S, *et al.* Curcumin, the major component of food flavour turmeric reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. *Br J Pharmacol* 2003; 139:209-218.
59. van't Land B, Blijlevens NMA, Martijn J, *et al.* Role of curcumin and the inhibition of NF- $\kappa$ B in the onset of chemotherapy-induced mucosal barrier injury. *Leukemia* 2004; 18:276-284.
60. Lim GP, Yang F, Chu T, *et al.* Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. *J Neurosci* 2000; 20:5709-5714.

61. Bjorkman D. Nonsteroidal anti-inflammatory drug-associated toxicity of liver, lower gastrointestinal tract, and esophagus. *Am J Med* 1998; 105:S17-S21.
62. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer disease. The Alzheimer disease cooperative study. *N Engl J Med* 1997; 336:1216-1222.
63. Zhao BL, Li XJ, He RG, et al. Scavenger effects of green tea and natural antioxidants on active oxygen radicals. *Cell Biophys* 1989; 14:175-185.
64. Sreejavan N, Rao MNA. Nitric oxide scavenging by curcumenoids. *J Pharm Pharmacol* 1997; 49:105-107.
65. Lim GP, Chu T, Yang F, et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. *J Neurosci* 2001; 21:8370-8377.
66. Frautschy SA, Hu W, Kim P, et al. Phenolic anti-inflammatory antioxidant reversal of A $\beta$ -induced cognitive deficits and neuropathology. *Neurobiol Aging* 2001; 22:993-1005.
67. Ganguli M, Chandra V, Kamboh MI, et al. Apolipoprotein E polymorphism and Alzheimer disease: the Ino-US cross-national dementia study. *Arch Neurol* 2000; 57:824-830.
68. Muthane U, Yasha TC, Shankar SK. Low numbers and no loss of melanized nigral neurons with increasing age in normal human brains from India. *Ann Neurol* 1998; 43:283-287.
69. Joseph JA, Shukitt-Hale B, Denisova NA, et al. Reversal of age-related declines in neuronal signal transduction, cognitive and motor behavioural deficits with blueberry, spinach and strawberry dietary supplementation. *J Neurosci* 1999; 19:8114-78121.
70. Rajakrishnan V, Viswanathan P, Rajasekharan N, Menon VP. Neuroprotective role of curcumin from *Curcuma longa* on ethanol-induced brain damage. *Phytother Res* 1999; 13:571-574.
71. Thylefors B. Prevention of blindness - WHO's mission for vision. *World Health Forum* 1998; 19:53-59.
72. Ughade SN, Zodepy SP, Khanolkar VA. Risk factors for cataract: a case control study. *Indian J Ophthalmol* 1998; 46:221-227.
73. Brian G, Taylor H. Cataract blindness - challenges for the 21st century. *Bull World Health Organ* 2001; 79:249-256.
74. Pandya U, Saini MK, Jin GF, et al. Dietary curcumin prevents ocular toxicity of naphthalene in rats. *Toxicology letters* 2000; 115:195-204.
75. Suryanarayana P, Krishnaswamy K, Reddy B. Effects on galactose-induced cataractogenesis in rats. *Molecular Vision* 2003; 9:223-230.
76. Padmaja S, Raju TN. Antioxidant effects in selenium induced cataract of Wistar rats. *Ind J Exp Biol* 2004; 42:601-603.
77. Gukocvsky I, Reyes CN, Vaquero EC, et al. Curcumin ameliorates ethanol and nonethanol experimental pancreatitis. *Am J Physiol Gastrointest Liver Physiol* 2003; 284:G85-G95.
78. Punithavathi DP, Venkatesan N, Babu M. Protective effects of curcumin against amiodarone-induced pulmonary fibrosis in rats. *Br J Pharmacol* 2003; 139:1342-1350.
79. Illek B, Lizarzaburu ME, Lee V, Nantz MH, Kurth MJ, Fischer H. Structural determinants for activation and block of CFTR-mediated chloride currents by apigenin. *Am J Physiol Cell Physiol* 2000; 279:C1838-C1844.
80. Egan ME, Pearson M, Weiner SA, et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. *Science* 2004; 304:600-602.
81. Zeitlin P. Can curcumin cure cystic fibrosis? *N Engl J Med* 2004; 351:606-608.
82. Ram A, Das M, Ghosh B. Curcumin attenuates allergen-induced hyperresponsiveness in sensitized guinea pigs. *Biol Pharm Bull* 2003; 26:1021-1024.
83. Shishodia S, Potdar P, Gairola CG, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF- $\kappa$ B activation through inhibition of I $\kappa$ B kinase in human lung cancer epithelial cells: correlation with suppression of COX-2, MM-9, cyclin D1. *Carcinogenesis* 2003; 7:1269-1279.
84. Bengmark S. Acute and "chronic" phase response - a mother of disease. *Clin Nutr*. 2004; 23:1256-1266.
85. Ott SJ, Wenderoth DF, Hampe J, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. *Gut* 2004; 53:685-693.
86. Finegold SM, Sutter VL, Mathisen GE. Normal indigenous intestinal flora. In: Hentges DJ, editor. *Human intestinal microflora in health and disease*. London; Academic Press, 1983, p 3-31.
87. Adlerberth I, Carlsson B, deMan P, et al. Intestinal colonization with Enterobacteriaceae in Pakistani and Swedish hospital-delivered infants. *Acta Paediatr Scandinav* 1991; 80:602-610.
88. Lencner AA, Lencner CP, Mikelsaar ME, et al. Die quantitative Zusammensetzung der Lactoflora des Verdauungstrakts vor und nach kosmischen Flügen unterschiedlicher Dauer Die Nahrung 1984; 28:607-613.
89. Knight DJW, Ala'Aldeen D, Bengmark S, Girling KJ. The effect of synbiotics on gastrointestinal flora in the critically ill. Abstract. *Br J Anaesth* 2004; 92:307P-308P.
90. Ahrné S, Nobaek S, Jeppsson B, et al. The normal lactobacillus flora in healthy human rectal and oral mucosa. *J Appl Microbiol* 1998; 85:88-94.
91. Müller M, Lier D. Fermentation of fructans by epiphytic lactic acid bacteria. *J Appl Bact* 1994; 76:406-411.
92. Naaber P, Smidt I, Stsepelova J, et al. Inhibition of *Clostridium difficile* strains by intestinal *Lactobacillus* species. *Med Microbiol* 2004; 53:551-554.
93. King DE, Egan BM, Geesey ME. Relation of dietary fat and fiber to elevation of C-reactive protein. *Am J Cardiol* 2003; 92:1335-1339.
94. Campbell TC, Junchi C. Diet and chronic degenerative diseases: perspective from China. *Am J Clin Nutr* 1994; 59:S1153-S1163.
95. Knekt P, Kumpulainen J, Järvinen R, et al. Flavonoid intake and risk of chronic diseases. *Am J Clin Nutr* 2002; 76:560-568.